Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-22
DOI
10.1038/s41401-020-0478-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo
- (2020) Jiann-Hwa Chen et al. Cancers
- ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma
- (2020) Ji Feng et al. ACTA PHARMACOLOGICA SINICA
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives
- (2019) Xin Sun et al. MEDICINAL RESEARCH REVIEWS
- Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma
- (2019) Wu Jing et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma
- (2019) Cho-Hao Lin et al. MOLECULAR CANCER THERAPEUTICS
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Antitumor effect of sorafenib and mTOR inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence
- (2018) Dong-Hwan Jung et al. LIVER TRANSPLANTATION
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma
- (2018) Wei-De Wu et al. Scientific Reports
- Artemisinin, the Magic Drug Discovered from Traditional Chinese Medicine
- (2018) Jigang Wang et al. Engineering
- Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis
- (2017) Jong-Lyel Roh et al. Redox Biology
- Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib
- (2016) Aline Houessinon et al. Molecular Cancer
- Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate
- (2016) Anna L. Greenshields et al. MOLECULAR CARCINOGENESIS
- ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
- (2016) Sebastian Doll et al. Nature Chemical Biology
- CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma
- (2015) Guo-Dong Lu et al. HEPATOLOGY
- Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum
- (2015) Jigang Wang et al. Nature Communications
- Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells
- (2015) Harish Chandra Pal et al. Oncotarget
- Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis
- (2015) Da Eun Jeong et al. Oncotarget
- Therapeutic effects of artesunate in hepatocellular carcinoma
- (2014) Yves-Paul Vandewynckel et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Artesunate Induces Cell Death in Human Cancer Cells via Enhancing Lysosomal Function and Lysosomal Degradation of Ferritin
- (2014) Nai-Di Yang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis
- (2014) Scott J Dixon et al. eLife
- Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion
- (2013) Jing Zhou et al. CELL RESEARCH
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
- (2012) Scott J. Dixon et al. CELL
- NIH Image to ImageJ: 25 years of image analysis
- (2012) Caroline A Schneider et al. NATURE METHODS
- Medical therapies for hepatocellular carcinoma: a critical view of the evidence
- (2012) Augusto Villanueva et al. Nature Reviews Gastroenterology & Hepatology
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2011) T. Yau et al. ONCOLOGIST
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo
- (2010) Gang Wei et al. INTERNATIONAL JOURNAL OF CANCER
- Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma
- (2009) D.-L. Ou et al. CLINICAL CANCER RESEARCH
- Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
- (2009) Pippa Newell et al. JOURNAL OF HEPATOLOGY
- Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation
- (2009) Kuen-Feng Chen et al. JOURNAL OF HEPATOLOGY
- Transferrin receptor-dependent cytotoxicity of artemisinin–transferrin conjugates on prostate cancer cells and induction of apoptosis
- (2008) Ikuhiko Nakase et al. CANCER LETTERS
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started